armaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. Ortho Biotech Products L.P. and the Janssen-Cilag group of companies will be responsible for commercialization in the EU and the rest of the world. Janssen Pharmaceutical K.K. will be responsible for Japan.

"With a substantial clinical programme already underway, we look forward to further developing this unique and exciting compound and possibly help patients with other types of cancers," said Ken Watters, European Medical Director, Ortho Biotech.

'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004

Page: 1 2 3
Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval